Last reviewed · How we verify
NCT04782713
Smart Prostate Specific Antigen (PSA) Screening Study
NA trial testing Completing surveys in PSA in 49 participants. Completed in 15 November 2024.
28 February 2022
Quick facts
| Lead sponsor | University of Illinois at Chicago |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 49 |
| Start date | 17 December 2021 |
| Primary completion | 28 February 2022 |
| Estimated completion | 15 November 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Completing surveys
Conditions studied
- PSA — all drugs for PSA →
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
University of Illinois at Chicago
Who can join
18 and older, any sex, with PSA or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This intervention includes the introduction of the Prostate Cancer Working Group (PCWG )Smart PSA Screening Guidelines and implementation of patient navigation/ care coordination for men with elevated PSA (\>4.0 ng/mL). The guidelines include: 1. What age to start? 2. How often to repeat screening? 3. What age to stop? 4. What PSA threshold should trigger a biopsy referral?
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population.
Gann PH, Stackhouse N, Gastala N, Ma W, et al · · 2026 · PMID 41761486 · DOI 10.1002/cncr.70340
Verify or expand the search:
- PubMed search for NCT04782713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PSA
Currently open trials in the same condition.
- NCT05629494 — Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test · Phase 4 · recruiting
- NCT04240327 — Marker Driven Selection of Patients for Prostate Biopsy and Management · active not recruiting
- NCT03784924 — EDRN Prostate MRI Biomarker Study · recruiting
- NCT03891732 — MRI Prostate for Chinese Men Being Screened for Prostate Cancer · active not recruiting
Other University of Illinois at Chicago trials
Trials by the same sponsor.
- NCT07498322 — Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System · NA · not yet recruiting
- NCT07387705 — On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial · Phase 1 · not yet recruiting
- NCT07504120 — The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis · NA · not yet recruiting
- NCT07160582 — Cognitive-Motor Training for AD/ADRD Prevention · NA · not yet recruiting
- NCT07498348 — Apple Watch Evaluation of Endodontics Occupational Stress · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04782713 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Illinois at Chicago
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04782713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing